Wart Remover

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by their rough, “cauliflower-like” appearance on the surface, while plantar warts are specifically located on the bottom of the foot, presenting with tenderness and an interruption of the footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly, and warts may be soaked in warm water for approximately 5 minutes to facilitate treatment. After soaking, the area must be dried completely.

The medication is to be applied by gently squeezing the tube to dispense one drop at a time, ensuring that each wart is sufficiently covered. It is important to allow the application to dry completely.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in patients with the following conditions:

Application on irritated skin, infected or reddened areas, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes is not recommended. This is particularly critical for individuals with diabetes or poor blood circulation due to the increased risk of complications in these populations.

Warnings and Precautions

For external use only; this product is flammable. In the event of accidental ingestion, immediate medical assistance should be sought by contacting a Poison Control Center at 1-800-222-1222.

This product should not be applied to irritated skin or any areas that are infected or reddened. It is contraindicated for use on birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes, particularly in individuals with diabetes or compromised blood circulation.

If discomfort persists following use, it is imperative to discontinue application and consult a healthcare professional for further evaluation and guidance.

Side Effects

Patients should be aware that the product is for external use only and is flammable. In the event of persistent discomfort, it is advised to stop use and consult a healthcare professional.

No additional serious or common adverse reactions have been reported in clinical trials or postmarketing experiences.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified in the available data. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Wart Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should not use this medication on irritated skin or on any area that is infected or reddened, including birthmarks, warts with hair growing from them, genital warts, or warts on the face or mucous membranes, particularly in those with diabetes or poor blood circulation.

For application, the affected area should be washed, and warts may be soaked in warm water for 5 minutes before drying the area thoroughly. The medication should be applied by gently squeezing the tube to dispense one drop at a time, ensuring each wart is sufficiently covered. This process may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

The product has not been specifically studied in pregnant patients, and there are no explicit statements regarding safety concerns, dosage modifications, or special precautions for use during pregnancy. Therefore, healthcare professionals should exercise caution when prescribing this product to women of childbearing potential. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Further research may be necessary to fully understand the implications of this product during pregnancy.

Lactation

There is no specific information regarding the use of WART REMOVER (salicylic acid liquid) in lactating mothers or its effects on breastfed infants. Healthcare professionals should exercise caution when considering the use of this product in nursing mothers due to the lack of available data.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information may necessitate individualized assessment and monitoring based on the patient's overall clinical status and renal function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be considered as part of standard clinical practice.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care and symptomatic treatment as necessary. This may include monitoring vital signs, providing respiratory support, and administering intravenous fluids if indicated.

Additionally, healthcare professionals should consider contacting a poison control center for guidance on specific management protocols tailored to the substance involved in the overdose.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important to instruct patients not to use the product on irritated skin or on any area that is infected or reddened. Patients should be cautioned against applying the product to birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes, particularly if they have diabetes or poor blood circulation.

Patients should be informed to discontinue use and consult a doctor if discomfort persists after application. Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes while using this product. In the event that the product comes into contact with the eyes, patients should be instructed to flush the eyes with water for 15 minutes. It is also advisable to warn patients against inhaling vapors from the product. Finally, patients should be reminded to cap the product tightly and store it at room temperature, away from heat sources.

Storage and Handling

The product is supplied in a tube format, with specific handling and storage requirements to ensure its integrity and effectiveness. It should be stored at room temperature, with a maximum temperature limit of 37°C (99°F) to avoid excessive heat exposure.

To maintain hygiene and prevent contamination, it is recommended to wipe the tip of the tube with a paper towel between uses. This practice helps to ensure that the product remains safe for application and retains its quality throughout its usage.

Additional Clinical Information

The product is administered topically, with the recommended frequency of application being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should counsel patients to avoid contact with the eyes; in the event of exposure, the eye should be flushed with water for 15 minutes. Patients are also advised to avoid inhaling vapors and to discontinue use if discomfort persists, seeking medical advice if necessary. In cases of ingestion, immediate medical assistance or contact with a Poison Control Center (1-800-222-1222) is recommended.

Drug Information (PDF)

This file contains official product information for Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)